Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
| − | ===[[QIBA_Profile_Stages# | + | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== |
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.1), June 26, 2017]] | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.1), June 26, 2017]] | ||
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist: SPECT Profile Conformance]] | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist: SPECT Profile Conformance]] | ||
Revision as of 21:23, 6 July 2017
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
Open for Public Comment. Submit comments here: http://tinyurl.com/QIBA-Public-Comment-Form
- DWI Profile 2017-04-27 Open until July 28, 2017
- QIBA PET Amyloid Profile 2017-06-15 Open until September 15, 2017
- QIBA fMRI Profile 2017-06-19 Open until September 19, 2017
Public Comment closed.
- QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016 (Closed Sept 2016)
- DCE-MRI Quantification 2011-12-13 (Closed Feb 2012)
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)